Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cue Biopharma, Inc. - Common Stock (NQ:CUE)

0.7175 -0.0501 (-6.53%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cue Biopharma, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at Two February 2023 Scientific Conferences
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Announces Chief Medical Officer Transition
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences
From Cue Biopharma, Inc.
Via GlobeNewswire
Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. (Nasdaq:CUE)
Via ACCESSWIRE
Cue Biopharma Reports Third Quarter 2022 Financial Results
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Presents New Positive Data from Ongoing Phase 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Host Business Update Call and Webcast
From Cue Biopharma, Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Good morning, traders! We're starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning! 
Via InvestorPlace
Why Soluna Holdings Shares Are Trading Sharply Lower; Here Are 38 Stocks Moving Premarket
Gainers Applied Genetic Technologies Corporation (NASDAQ: AGTC) rose 70.8% to $0.41 in pre-market trading. Syncona disclosed that it will acquire Applied Genetic Technologies Corporation. 
Via Benzinga
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers 
Via Benzinga
Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session
Gainers Bit Brother Limited (NASDAQ: BTB) rose 229% to $0.3688 after declining around 14% on Monday. 
Via Benzinga
Cue Biopharma Granted FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
From Cue Biopharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
  
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
Cue Biopharma Shares Decline Following Initial-Stage Metastatic Cancer Study Kicks-off
Cue Biopharma (NASDAQ: CUE) has dosed the first patient in a Phase 1 dose escalation study evaluating CUE-102 for the treatment of patients with Wilms' Tumor 1 (WT1)-positive recurrent/metastatic... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 87 companies hit new 52-week lows. 
Via Benzinga
Cue Biopharma's Return On Capital Employed Overview
Benzinga Pro data, Cue Biopharma (NASDAQ:CUE) reported Q1 sales of $1.00 million. Earnings fell to a loss of $14.26 million, resulting in a 70.02% decrease from last quarter. 
Via Benzinga
FDA Accepts IND for Cue Biopharma's CUE-102 in the treatment of Wilms' Tumor 1 (WT1)
Cue Biopharma, Inc. (NASDAQ: CUE) received the U.S. Food and Drug Administration (FDA) acceptance of the Investigational New Drug (IND) application for the evaluation of CUE-102 in the treatment of... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Sunshine Biopharma (NASDAQ:SBFM) shares moved upwards by 163.3% to $5.95 during Tuesday's pre-market session. The market value of their outstanding shares is... 
Via Benzinga
Looking Into Cue Biopharma's Return On Capital Employed
According to data from Benzinga Pro, during Q4, Cue Biopharma's (NASDAQ:CUE) reported sales totaled $8.25 million. Despite a 35.47% increase in earnings, the company posted a loss... 
Via Benzinga
64 Biggest Movers From Yesterday
Gainers Kidpik Corp. (NASDAQ: PIK) shares surged 158.2% to settle at $4.75 on Thursday after the company announced a partnership with The Walt Disney Co. Cuentas Inc. (NASDAQ:... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 109 companies set new 52-week lows. Interesting Points From Today's 52-Week Highs And Lows: The largest company in terms of market cap... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.